NXTC vs OESX Comparison

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Orion Energy Systems Inc is engaged in light-emitting diode lighting systems, wireless Internet of Things-enabled control solutions, project engineering, energy project management design, maintenance services, and turnkey electric vehicle charging stations and related installation services to commercial and industrial businesses, and federal and local governments, predominantly in North America. The group has three segments: the Orion lighting segment, the Orion maintenance segment, and the Orion electric vehicle charging segment. It generates the majority of its revenue from the Orion lighting segment, which develops and sells lighting products and provides construction and engineering services for Orion's commercial lighting and energy management systems.